Patents Assigned to Axial Therapeutics, Inc.
-
Patent number: 11951094Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.Type: GrantFiled: June 15, 2022Date of Patent: April 9, 2024Assignee: Axial Therapeutics, Inc.Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
-
Patent number: 11883537Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.Type: GrantFiled: January 12, 2022Date of Patent: January 30, 2024Assignee: Axial Therapeutics, Inc.Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
-
Patent number: 11744820Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.Type: GrantFiled: September 8, 2021Date of Patent: September 5, 2023Assignees: Axial Therapeutics, Inc., California Institute of TechnologyInventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
-
Publication number: 20230131899Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.Type: ApplicationFiled: January 8, 2021Publication date: April 27, 2023Applicant: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, Christopher J. Oalmann, Dennis S. Yamashita
-
Publication number: 20230113225Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathics such as Parkinson's Disease.Type: ApplicationFiled: August 4, 2022Publication date: April 13, 2023Applicant: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
-
Publication number: 20230103887Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.Type: ApplicationFiled: August 4, 2022Publication date: April 6, 2023Applicant: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
-
Publication number: 20230051773Abstract: The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.Type: ApplicationFiled: June 15, 2022Publication date: February 16, 2023Applicant: Axial Therapeutics, Inc.Inventors: Christopher J. Oalmann, Dennis S. Yamashita, Patrick J. Stern
-
Patent number: 11505528Abstract: The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.Type: GrantFiled: August 6, 2018Date of Patent: November 22, 2022Assignee: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, Bridget Cole, Alessandra Bartolozzi
-
Publication number: 20220133634Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.Type: ApplicationFiled: January 12, 2022Publication date: May 5, 2022Applicant: Axial Therapeutics, Inc.Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
-
Patent number: 11278498Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.Type: GrantFiled: November 5, 2020Date of Patent: March 22, 2022Assignee: Axial Therapeutics, Inc.Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
-
Patent number: 11147792Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.Type: GrantFiled: May 14, 2018Date of Patent: October 19, 2021Assignees: AXIAL THERAPEUTICS, INC., CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Timothy Sampson, Sarkis Mazmanian, Anthony Stewart Campbell
-
Patent number: 11007219Abstract: The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.Type: GrantFiled: June 10, 2020Date of Patent: May 18, 2021Assignee: Axial Therapeutics, Inc.Inventors: Anthony Stewart Campbell, David H. Donabedian
-
Publication number: 20210052503Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.Type: ApplicationFiled: November 5, 2020Publication date: February 25, 2021Applicant: Axial Therapeutics, Inc.Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell